Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219048
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCámara Navarro, Yolanda-
dc.contributor.authorCarreño-Gago, Lidia-
dc.contributor.authorMartín, Miguel A.-
dc.contributor.authorMelià, Maria J.-
dc.contributor.authorBlázquez, Alberto-
dc.contributor.authorDelmiro, Aitor-
dc.contributor.authorGarrabou Tornos, Glòria-
dc.contributor.authorMorén Núñez, Constanza-
dc.contributor.authorDíaz-Manera, Jorge-
dc.contributor.authorGallardo, Eduardo-
dc.contributor.authorBornstein, Belén-
dc.contributor.authorLópez Gallardo, Ester-
dc.contributor.authorHernández-Lain, Aurelio-
dc.contributor.authorSan Millán, Beatriz-
dc.contributor.authorCancho, Esther-
dc.contributor.authorRodríguez Vico, Jaime-
dc.contributor.authorMartí, Ramon-
dc.contributor.authorGarcía Arumí, Elena-
dc.date.accessioned2025-02-20T16:11:04Z-
dc.date.available2025-02-20T16:11:04Z-
dc.date.issued2015-05-06-
dc.identifier.issn0028-3878-
dc.identifier.urihttps://hdl.handle.net/2445/219048-
dc.description.abstractThymidine kinase 2 (TK2) is a mitochondrial enzyme participating in the salvage of deoxyribonucleotides needed for mitochondrial DNA (mtDNA) replication. TK2 catalyzes the first and rate-limiting step of the deoxypyrimidine salvage pathway. Mutations in TK2 were typically associated with a severe myopathic form of mtDNA depletion syndrome (MDS) characterized by a dramatic decrease in mtDNA copy number in muscle that manifests during infancy and leads to the early death of most patients.1 Recently, several patients have been diagnosed with a late-onset or slow-progressing form of the disease manifesting as a milder myopathy with mtDNA multiple deletions.2–5 Here we describe 7 adult cases presenting with a mild myopathy compatible with a relatively normal life for decades and associated with multiple mtDNA deletions and no marked depletion in skeletal muscle. TK2 activity was drastically reduced in cultured fibroblasts of 2 of these patients, suggesting that redundant or complementary biochemical mechanisms could bypass the defect in some individuals, in contrast with severely affected infantile patients.-
dc.format.extent3 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherLippincott, Williams & Wilkins. Wolters Kluwer Health-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1212/WNL.0000000000001644-
dc.relation.ispartofNeurology, 2015, vol. 84, num.22, p. 2286-2288-
dc.relation.urihttps://doi.org/10.1212/WNL.0000000000001644-
dc.rights(c) American Academy of Neurology, 2015-
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationProteïnes-
dc.subject.classificationFibroblasts-
dc.subject.classificationMalalties musculars-
dc.subject.otherProteins-
dc.subject.otherFibroblasts-
dc.subject.otherMuscular Diseases-
dc.titleSevere TK2 enzyme activity deficiency in patients with mild forms of myopathy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec661732-
dc.date.updated2025-02-20T16:11:04Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
192506.pdf68.95 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.